Listing of various contrast media
PHARMAC is pleased to announce decisions relating to the listing of contrast media agents that will take effect from 1 July 2014 under agreements with GE Healthcare, Bayer, Obex Medical and Global Medical Solutions. These agreements were the subject of a consultation letter dated 1 May 2014.
In summary, the effect of the decision is that the following products will be listed in Part II of Section H of the Pharmaceutical Schedule:
- In relation to Bayer New Zealand Limited
- diatrizoate meglumine with sodium amidotrizoate (Gastrografin and Urografin)
- gadobutrol (Gadovist)
- gadoxetate disodium (Primovist)
- meglumine gadopentate (Magnevist)
- meglumine iotrexate (Biliscopin)
- In relation to GE Healthcare Limited
- gadodiamide (Omniscan)
- iohexol (Omnipaque)
- iodixanol (Visipaque)
- In relation to Global Medical Solutions (NZ) Limited
- perflutren (Definity)
- perflutren (Definity)
- In relation to Obex Medical Limited
- gadoteric acid (Dotarem)
- iodised oil (Lipiodol Ultra Fluid)
- patent blue V (Patent Blue V)
Omnipaque, Visipaque and Definity will be awarded Hospital Sole Supply status for the non-ionic monomer, non-ionic dimer and ultrasound contrast media markets respectively from 1 September 2014 until 30 June 2017.
Details of the decision
The following listings will take effect in Part II of Section H of the Pharmaceutical Schedule from 1 July 2014:
| Chemical | Presentation | Pack size | Brand | Price ex manufacturing, exclusive of GST |
|---|---|---|---|---|
| Iohexol | Inj 240 mg per ml (iodine equivalent), 50 ml bottle | 10 | Omnipaque | $75.00 |
| Iohexol | Inj 300 mg per ml (iodine equivalent), 20 ml bottle | 10 | Omnipaque | $57.00 |
| Iohexol | Inj 300 mg per ml (iodine equivalent), 50 ml bottle | 10 | Omnipaque | $75.00 |
| Iohexol | Inj 300 mg per ml (iodine equivalent), 100 ml bottle | 10 | Omnipaque | $150.00 |
| Iohexol | Inj 350 mg per ml (iodine equivalent), 20 ml bottle | 10 | Omnipaque | $59.00 |
| Iohexol | Inj 350 mg per ml (iodine equivalent), 50 ml bottle | 10 | Omnipaque | $75.00 |
| Iohexol | Inj 350 mg per ml (iodine equivalent), 75 ml bottle | 10 | Omnipaque | $114.00 |
| Iohexol | Inj 350 mg per ml (iodine equivalent), 100 ml bottle | 10 | Omnipaque | $150.00 |
| Iohexol | Inj 350 mg per ml (iodine equivalent), 200 ml bottle | 10 | Omnipaque | $290.00 |
| Iodixanol | Inj 270 mg per ml (iodine equivalent), 50 ml bottle | 10 | Visipaque | $220.00 |
| Iodixanol | Inj 270 mg per ml (iodine equivalent), 100 ml bottle | 10 | Visipaque | $430.00 |
| Iodixanol | Inj 320 mg per ml (iodine equivalent), 50 ml bottle | 10 | Visipaque | $220.00 |
| Iodixanol | Inj 320 mg per ml (iodine equivalent), 100 ml bottle | 10 | Visipaque | $430.00 |
| Iodixanol | Inj 320 mg per ml (iodine equivalent), 200 ml bottle | 10 | Visipaque | $850.00 |
| Gadodiamide | Inj 287 mg per ml, 10 ml prefilled syringe | 10 | Omniscan | $200.00 |
| Gadodiamide | Inj 287 mg per ml, 15 ml prefilled syringe | 10 | Omniscan | $320.00 |
| Gadodiamide | Inj 287 mg per ml, 10 ml vial | 10 | Omniscan | $170.00 |
| Gadodiamide | Inj 287 mg per ml, 5 ml vial | 10 | Omniscan | $120.00 |
| Meglumine gadopentetate | Inj 469 mg per ml, 10 ml prefilled syringe | 5 | Magnevist | $95.00 |
| Meglumine gadopentetate | Inj 469 mg per ml, 10 ml vial | 10 | Magnevist | $185.00 |
| Diatrizoate meglumine with sodium amidotrizoate | Oral liq 660 mg per ml with sodium amidotrizaote 100 mg per ml, 100 ml bottle | 100 ml | Gastrografin | $22.50 |
| Gadobutrol | Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled syringe | 5 | Gadovist | $180.00 |
| Gadobutrol | Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled syringe | 10 | Gadovist | $700.00 |
| Gadoxetate disodium | Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefilled syringe | 1 | Primovist | $300.00 |
| Diatrizoate meglumine with sodium amidotrizoate | Inj 146 mg per ml with sodium amidotrizaote 40 mg per ml, 250 ml bottle | 1 | Urografin | $80.00 |
| Meglumine iotrexate | Inj 105 mg per ml, 100 ml bottle | 100 ml | Biliscopin | $150.00 |
| Perflutren | Inj 1.1 mg per ml, 1.5 ml vial | 1 | Definity | $180.00 |
| Perflutren | Inj 1.1 mg per ml, 1.5 ml vial | 4 | Definity | $720.00 |
| Gadoteric acid | Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle | 1 | Dotarem | $12.30 |
| Gadoteric acid | Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle | 1 | Dotarem | $23.20 |
| Gadoteric acid | Inj 279.32 mg per ml (0.5 mmol ml), 15 ml bottle | 1 | Dotarem | $34.50 |
| Gadoteric acid | Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle | 1 | Dotarem | $46.30 |
| Gadoteric acid | Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe | 1 | Dotarem | $24.50 |
| Gadoteric acid | Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe | 1 | Dotarem | $41.00 |
| Gadoteric acid | Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml prefilled syringe | 1 | Dotarem | $55.00 |
| Iodised oil | Inj 38% W/W (480 mg iodine per ml), 10 ml ampoule | 1 | Lipiodol Ultra Fluid | $143.00 |
| Patent blue V | Inj 2.5%, 2 ml ampoule | 5 | Obex Medical | $440.00 |
The following products will be delisted from 1 July 2014:
- diatrizoate meglumine with diatrizoate sodium inj 370 mg with sodium amidotrizoate 100 mg per ml, 50 ml bottle
- diatrizoate meglumine with diatrizoate sodium (Gastrograffin) inj 146 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle
- gadodiamide (Omniscan) inj 287 mg per ml, 15 ml vial, 10 vial pack size; 20 ml syringe, 10 syringe pack size; and 20 ml vial
- iodixanol (Visipaque) inj 320 mg per ml, 150 ml bottle, 10 bottle pack size; and 200 ml bottle, 6 bottle pack size
- iohexol (Omnipaque) inj 300 mg per ml, 20 ml bottle, 6 bottle pack size; and 500 ml bottle, 6 bottle pack
- iohexol (Omnipaque) inj 350 mg per ml, 20 ml bottle, 6 bottle pack size
- iomeprol – all presentations ;
- iopromide – all presentations;
- iotrolan inj 240 mg per ml, 10 ml vial;
- meglumine gadopentate inj 469 mg per ml, 15 ml vial and 20 ml vial
Feedback received
We appreciate all of the feedback that we received and acknowledge the time people took to respond. All consultation responses received by 16 May 2014 were considered in their entirety in making a decision on the proposed changes. Most responses were supportive of the proposal, and the following issues were raised in relation to specific aspects of the proposal:
| Theme | Comment |
|---|---|
| Several respondents commented that gadobenic acid was used in their hospitals but was not included in the list of products proposed to be listed. | Gadobenic acid is supplied by another company and PHARMAC is in discussion with the supplier. |
| Two responders commented that Urografin was used in their hospitals but was not included in the list of products proposed to be listed. | This product has been added and will be listed effective 1 July 2014. |
| One respondent expressed concern that hospital supply status (HSS) may reduce competition in the market. | Sole supply for the monomer and dimer non-ionic agents allows for savings to be made for DHBs and security of supply in return for surety of the market for the supplier. A DV limit allows for some usage of other products if there is a clinical reason for not being able to use the HSS product. This decision does not prevent other suppliers from participating in future competitive processes in this market after 30 June 2017. |
More information
If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.